Molecular Profiles Invests in Hot Melt Extrusion Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Molecular Profiles Invests in Hot Melt Extrusion Technology


Molecular Profiles, a UK-based pharmaceutical development and manufacturing services provider, has invested in GMP hot melt extrusion (HME) technology along with other milling equipment. The expansion is part of a wider project focusing on enabling technologies to accelerate formulation development, particularly for complex molecules that are difficult to progress.

Rob Harris, chief technical officer at Molecular Profiles, said in a press statement that expanding the company’s in-house equipment would complement its expertise by bringing on-stream a diverse range of enabling technologies to assist drug developers in developing challenging compounds. According to Harris, the new enabling technologies division forms the backbone of the company’s early formulation development services, which primarily specialize in screening formulation options for challenging compounds, developing effective formulations, and finding solutions to meet clients’ product development requirements.

This investment marked a significant venture for Molecular Profiles. The company opened its new clinical production site in July 2013 following a successful inspection from the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Molecular Profiles manufactures a range of dosage forms for clinical trials spanning solids, liquids, semi-solids and inhaled products, including potent compounds.

Source: Molecular Profiles

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here